Tatva Chintan Pharma Q4 EBITDA Jumps to ₹281M; FY26 Net Profit Surges to ₹420.54M

Tatva Chintan Pharma Chem Limited's Board of Directors, at its meeting held on 16 May 2026, approved the audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026, pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors, M/s. NDJ & Co., Chartered Accountants, Surat (Firm Registration No. 136345W), issued an unmodified audit opinion on both the standalone and consolidated financial results. The results were reviewed by the Audit Committee and approved by the Board at the meeting, which commenced at 12:30 P.M. and concluded at 03:05 P.M.

Q4 Operational Highlights

Tatva Chintan Pharma Chem delivered a strong operational performance in Q4, with EBITDA surging to ₹281 million compared to ₹89.5 million in the same quarter of the previous year, reflecting a sharp year-on-year improvement. The EBITDA margin expanded significantly to 21% from 8.3% in the corresponding prior-year period, underscoring improved cost efficiency and operating leverage. On a consolidated basis, Q4 net profit rose to ₹103 million versus ₹10.3 million in Q4 of the prior year, while Q4 revenue stood at ₹1.3 billion compared to ₹1.1 billion year-on-year.

Metric: Q4 FY26 Q4 FY25 (YoY) EBITDA (₹ mn): 281.00 89.50 EBITDA Margin (%): 21.00 8.30 Consolidated Net Profit (₹ mn): 103.00 10.30 Revenue (₹ bn): 1.30 1.10

Consolidated Financial Performance

The company's consolidated financial results for the year ended 31 March 2026 reflect a significant improvement over the prior year. Revenue from operations rose to ₹5,058.58 million in FY26 from ₹3,827.14 million in FY25. Total income, including other income, stood at ₹5,094.07 million for FY26 compared to ₹3,850.29 million in FY25. Net profit for the year surged to ₹420.54 million from ₹57.13 million in the previous year, while total comprehensive income reached ₹452.74 million against ₹64.20 million in FY25.

The following table summarises the consolidated financial results:

Metric: Q4 FY26 (Unaudited) Q3 FY26 (Unaudited) Q4 FY25 (Unaudited) FY26 (Audited) FY25 (Audited) Revenue from Operations (₹ mn): 1,341.44 1,313.34 1,078.64 5,058.58 3,827.14 Total Income (₹ mn): 1,337.96 1,330.68 1,085.86 5,094.07 3,850.29 Total Expenses (₹ mn): 1,172.09 1,154.10 1,065.59 4,523.98 3,774.50 Profit Before Tax (₹ mn): 165.87 176.58 20.27 570.09 75.79 Net Profit (₹ mn): 103.21 151.65 10.30 420.54 57.13 Total Comprehensive Income (₹ mn): 117.23 156.48 11.71 452.74 64.20 Basic EPS (₹): 4.41 6.49 0.44 17.98 2.44 Diluted EPS (₹): 4.41 6.49 0.44 17.98 2.44

Standalone Financial Performance

On a standalone basis, revenue from operations for FY26 was ₹4,962.96 million compared to ₹3,664.15 million in FY25. Profit before tax stood at ₹531.65 million for FY26, a substantial improvement from ₹4.61 million in FY25. Net profit after tax for FY26 was ₹390.82 million against ₹3.27 million in FY25, while total comprehensive income reached ₹392.56 million compared to ₹1.10 million in the prior year.

Metric: Q4 FY26 (Unaudited) Q3 FY26 (Unaudited) Q4 FY25 (Unaudited) FY26 (Audited) FY25 (Audited) Revenue from Operations (₹ mn): 1,326.65 1,385.88 1,076.48 4,962.96 3,664.15 Profit Before Tax (₹ mn): 149.75 187.92 15.54 531.65 4.61 Net Profit After Tax (₹ mn): 90.23 159.84 10.95 390.82 3.27 Total Comprehensive Income (₹ mn): 91.66 161.54 10.38 392.56 1.10 Basic EPS (₹): 3.86 6.84 0.47 16.71 0.14 Diluted EPS (₹): 3.86 6.84 0.47 16.71 0.14

Balance Sheet Highlights

As at 31 March 2026, the consolidated total assets of the company stood at ₹10,036.94 million compared to ₹8,362.49 million as at 31 March 2025. Total equity attributable to owners was ₹7,817.59 million as against ₹7,388.24 million in the prior year. Paid-up equity share capital remained unchanged at ₹233.92 million, and other equity (excluding revaluation reserve) stood at ₹7,583.67 million on a consolidated basis. On a standalone basis, total assets were ₹9,953.82 million as at 31 March 2026 compared to ₹8,228.01 million as at 31 March 2025. Total standalone equity was ₹7,582.29 million against ₹7,213.12 million in the prior year.

Dividend and Other Board Decisions

The Board recommended a final dividend of Rs. 2/- (20%) per equity share of face value Rs. 10/- each, on the equity share capital of Rs. 23,39,20,550/- (2,33,92,055 equity shares of Rs. 10/- each) for the financial year 2025-26. This dividend is subject to deduction of tax, if any, and to the approval of shareholders at the ensuing Annual General Meeting.

In addition to the financial results and dividend recommendation, the Board approved the following appointments for the financial year 2026-27:

Appointment: Details Cost Auditor: M/s. Zarna Thakar & Associates, Cost Accountants Appointment Date: 16 May 2026 Scope: Audit of cost records for FY2026-27 Internal Auditor: RSM Astute Consultech Private Limited Appointment Date: 16 May 2026 Scope: Internal audit for FY2026-27

M/s. Zarna Thakar & Associates is a Cost & Management Accounting firm with 10+ years of experience and a Pan-India presence, having conducted cost audits for 100+ companies across industries including chemicals, pharmaceuticals, engineering, textiles, mining, and plastics. RSM Astute Consultech Private Limited is part of RSM India, which ranks amongst India's top 6 audit, tax and consulting groups and is part of RSM International, with offices in 14 key cities across India. The remuneration of the Cost Auditor is subject to shareholder approval at the ensuing Annual General Meeting.

Segment and Auditor Details

The company operates in a single reportable business segment — specialty chemicals — and accordingly, segment disclosure is not required as per Ind AS 108 - Operating Segments. The consolidated financial results include the results of subsidiaries Tatva Chintan USA Inc. and Tatva Chintan Europe B.V. The results were signed by Chintan N. Shah, Chairman and Managing Director (DIN: 00183618), on behalf of the Board of Directors, from Vadodara, Gujarat, India, on 16 May 2026.

Tatva Chintan Pharma Chem Limited has announced, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that an earnings call to discuss the financial results for the quarter and financial year ended March 31, 2026, is scheduled for Saturday, May 16, 2026. The call is set to commence at 5:00 p.m. IST and is being hosted by ICICI Securities. This announcement follows the company's previous intimation regarding a board meeting convened on the same date to consider and approve the audited financial results.

Board Meeting Agenda

The board meeting on May 16, 2026, will primarily focus on the company's financial performance for the fiscal year. The agenda includes the consideration and approval of the Standalone and Consolidated Audited Financial Results for the quarter and year ended March 31, 2026. Additionally, the board will consider recommending a final dividend on equity shares for FY26, subject to shareholder approval at the upcoming Annual General Meeting.

Agenda Item Details Financial Results Consider and approve Standalone and Consolidated Audited Financial Results for Q4 and FY26 Dividend Consider and recommend a final dividend for FY26, if any Meeting Date Saturday, May 16, 2026 Earnings Call Time 05:00 p.m. IST

Earnings Call Details

The post-results conference call will be represented by key company officials, including Mr. Chintan Shah, Managing Director, and Mr. Ajesh Pillai, Chief Financial Officer. The event provides a platform for the management to discuss the financial performance and outlook with investors and analysts. ICICI Securities has provided a Diamond Pass registration link for participants wishing to join the session.

Trading Window Closure

In compliance with the Company's Code of Conduct for Prohibition of Insider Trading, the trading window for designated persons was closed effective April 1, 2026. This closure will remain in effect until the expiry of 48 hours from the date the financial results are made public to the stock exchanges. The intimation regarding these schedules has been filed with BSE Limited and the National Stock Exchange of India Limited.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.